Diabetes Res Clin Pract 2018;pii:S0168-8227:30554-0.
32Bahri Khomami M, Boyle JA, Tay CT, Vanky E, Teede HJ, Joham AE, Moran LJ: Polycystic ovary syndrome and adverse pregnancy outcomes: Current state of knowledge, challenges and potential implications for practice. Clin Endocrinol (Oxf) 2018;88:761–769.
33Weiss PAM, Scholz HS, Haas J, Tamussino KF, Seissler J, Borkenstein MH: Long-term follow-up of diabetes of mothers with type I diabetes: evidence for hereditary and nonhereditary transmission of diabetes and precursors. Diabetes Care 2000;23:905–911.
34Homburg R, Gudi A, Shah A, M Layton A: A novel method to demonstrate that pregnant women with polycystic ovary syndrome hyper-expose their fetus to androgens as a possible stepping stone for the developmental theory of PCOS. A pilot study. Reprod Biol Endocrinol 2017;15:61.
35Barrett ES, Hoeger KM, Sathyanarayana S, Abbott DH, Redmon JB, Nguyen RHN, Swan SH: Anogenital distance in newborn daughters of women with polycystic ovary syndrome indicates fetal testosterone exposure. J Dev Orig Health Dis 2018;9:307–314.
36Abbott AD, Colman RJ, Tiefenthaler R, Dumesic DA, Abbott DH: Early-to-mid gestation fetal testosterone increases right hand 2D:4D finger length ratio in polycystic ovary syndrome-like monkeys. PLoS One 2012;7:e42372.
37Sánchez-Ferrer ML, Mendiola J, Hernández-Peñalver AI, Corbalán-Biyang S, Carmona-Barnosi A, Prieto-Sánchez MT, Nieto A, Torres-Cantero AM: Presence of polycystic ovary syndrome is associated with longer anogenital distance in adult Mediterranean women. Hum Reprod 2017;32:2315–2323.
38Wu Y, Zhong G, Chen S, Zheng C, Liao D, Xie M: Polycystic ovary syndrome I associated with anogenital distance, a marker of prenatal androgen exposure. Hum Reprod 2017;32:937–943.
39Lujan ME, Bloski TG, Chizen DR, Lehotay DC, Pierson RA: Digit ratios do not serve as anatomical evidence of prenatal androgen exposure in clinical phenotypes of polycystic ovary syndrome. Hum Reprod 2010;25:204–211.
40Torchen LC, Idkowiak J, Fogel NR, O’Neil DM, Shackleton CH, Arlt W, Dunaif A: Evidence for increased 5α-reductase activity during early childhood in daughters of women with polycystic ovary syndrome. J Clin Endocrinol Metab 2016;101:2069–2075.
41Barry JA, Kay AR, Navaratnarajah R, Iqbal S, Bamfo JE, David AL, Hines M, Hardiman PJ: Umbilical vein testosterone in female infants born to mothers with polycystic ovary syndrome is elevated to male levels. J Obstet Gynaecol 2010;30:444–446.
42Daan NM, Koster MP, Steegers-Theunissen RP, Eijkemans MJ, Fauser BC: Endocrine and cardiometabolic cord blood characteristics of offspring born to mothers with and without polycystic ovary syndrome. Fertil Steril. 2017;107:261–268.e3.
43Caanen MR, Kuijper EA, Hompes PG, Kushnir MM, Rockwood AL, Meikle WA, Homburg R, Lambalk CB: Mass spectrometry methods measured androgen and estrogen concentrations during pregnancy and in newborns of mothers with polycystic ovary syndrome. Eur J Endocrinol 2016;174:25–32.
44Anderson H, Fogel N, Grebe SK, Singh RJ, Taylor RL, Dunaif A: Infants of women with polycystic ovary syndrome have lower cord blood androstenedione and estradiol levels. J Clin Endocrinol Metab 2010;95:2180–2186.
45Hollier LP, Keelan JA, Hickey M, Maybery MT, Whitehouse AJ: Measurement of androgen and estrogen concentrations in cord blood: accuracy, biological interpretation, and applications to understanding human behavioral development. Front Endocrinol (Lausanne) 2014;5:64.
46McAllister JM, Legro RS, Modi BP, Strauss JF 3rd: Functional genomics of PCOS: from GWAS to molecular mechanisms. Trends Endocrinol Metab 2015;26:118–124.
47Dunaif A: Perspectives in polycystic ovary syndrome: from hair to eternity. J Clin Endocrinol Metab 2016;101:759–768.
48Pau CT, Mosbruger T, Saxena R, Welt CK: Phenotype and tissue expression as a function of genetic risk in polycystic ovary syndrome. PLoS One 2017;12:e0168870.
49Gorsic LK, Kosova G, Werstein B, Sisk R, Legro RS, Hayes MG, Teixeira JM, Dunaif A, Urbanek M: Pathogenic anti-Müllerian hormone variants in polycystic ovary syndrome. J Clin Endocrinol Metab 2017;102:2862–2872.
50Vink JM, Sadrzadeh S, Lambalk CB, Boomsma DI: Heritability of polycystic ovary syndrome in a Dutch twin-family study. J Clin Endocrinol Metab 2006;91:2100–2104.
51Nugent BM, Bale TL: The omniscient placenta: Metabolic and epigenetic regulation of fetal programming. Front Neuroendocrinol 2015;39:28–37.
52Corso-Díaz X, Jaeger C, Chaitankar V, Swaroop A: Epigenetic control of gene regulation during development and disease: a view from the retina. Prog Retin Eye Res 2018;65:1–27.
53Li S, Zhu D, Duan H, Tan Q: The epigenomics of polycystic ovarian syndrome: from pathogenesis to clinical manifestations. Gynecol Endocrinol 2016;32:942–946.
54Ibáñez L, Oberfield SE, Witchel S, Auchus RJ, Chang RJ, Codner E, Dabadghao P, Darendeliler F, Elbarbary NS, Gambineri A, Garcia Rudaz C, Hoeger KM, López-Bermejo A, Ong K, Peña AS, Reinehr T, Santoro N, Tena-Sempere M, Tao R, Yildiz BO, Alkhayyat H, Deeb A, Joel D, Horikawa R, de Zegher F, Lee PA: An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr 2017;88:371–395.
55Wang P, Zhao H, Li T, Zhang W, Wu K, Li M, Bian Y, Liu H, Ning Y, Li G, Chen ZJ: Hypomethylation of the LH/choriogonadotropin receptor promoter region is a potential mechanism underlying susceptibility to polycystic ovary syndrome. Endocrinology 2014;155:1445–1452.
56Jones MR, Brower MA, Xu N, Cui J, Mengesha E, Chen YD, Taylor KD, Azziz R, Goodarzi MO: Systems genetics reveals the functional context of PCOS loci and identifies genetic and molecular mechanisms of disease heterogeneity. PLoS Genet 2015;11:e1005455.
57Song J, Luo S, Li SW: miRNA-592 is downregulated and may target LHCGR in polycystic ovary syndrome patients. Reprod Biol 2015;15:229–237.